Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameDual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-HER2Programmed death-ligand 1 blockersCell replacements

TargetsReceptor protein-tyrosine kinase erbB-2Programmed death-ligand 1

Therapy Area/IndicationsPleural Effusion, MalignantPeritoneal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesSichuan University

China Registration ClassN/A

Develop Information

Active CompaniesSichuan University

Inactive CompaniesN/A

Active IndicationsPleural Effusion, MalignantPeritoneal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A